In human medicine, new evidence supports the use of Galectin-3 (Gal-3), soluble interleukin-1 receptor-like 1 protein (sST2) (Bayes-Genis et al., 2014; Emdin et al., 2018), and growth differentiation factor 15 (GDF-15) (Sharma et al., 2017) as predictors of outcomes and mortality in patients with various chronic inflammatory diseases, including HF. Here, LGALS3 is linked to hydrops fetalis.